Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.52 +0.07 (+0.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
After Plummeting More Than 23%, Is Exelixis a Buy?
The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced. 
Via The Motley Fool
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?
The biotech stock plunged after disappointing clinical results. 
Via The Motley Fool
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
From Exelixis, Inc.
Via Business Wire
Fireworks Display
The oil price rose to 76.81/bbl after the OPEC attempt to have a meeting to agree to boost production (and cut prices) was blocked. 
Via Talk Markets
End Of June
Canadian Solar fell 4.6% on fears of plans for a China IPO where its panels are made. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
June’s Best and Worst Performing Russell 1,000 Stocks
The month of June, the second quarter and the first half of 2021 are almost in the bag. 
Via Talk Markets
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Exelixis Stock Collapses; Can It Recover From Mixed Results In Liver Cancer Study?
Exelixis reported mixed results for its advanced liver cancer treatment on Monday and EXEL stock collapsed to a seven-month low. 
Via Investor's Business Daily
60 Biggest Movers From Yesterday
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Intellia Therapeutics (NASDAQ:NTLA 
Via Benzinga
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Here's Why Exelixis Stock Is Dropping Today
The company reported successful clinical trial results, but investors were still disappointed. 
Via The Motley Fool
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion.... 
Via Benzinga
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (NYSE: LLY) stood out among big... 
Via Benzinga
Exposures Product Safety
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
From Exelixis, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Unheeding Markets
Today oil prices rose over $70. 
Via Talk Markets
Here's What Crushed Exelixis' Earnings
R&D spending is hurting earnings, but long-term investors shouldn't be worried. 
Via The Motley Fool
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
From Exelixis, Inc.
Via Business Wire
2 Top Biotech Stocks to Buy Right Now
One is growing revenue. And the other may soon launch its first product. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.